Cover Image
市場調查報告書

藥物分析:Durvalumab (Imfinzi)

Drug Analysis: Imfinzi

出版商 Datamonitor Healthcare 商品編碼 603913
出版日期 內容資訊 英文 41 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物分析:Durvalumab (Imfinzi) Drug Analysis: Imfinzi
出版日期: 2017年12月01日 內容資訊: 英文 41 Pages
簡介

本報告提供PD-L1為目標的人單株抗體的Durvalumab (Imfinzi) 的相關調查,提供主要國家/地區的銷售額實際成果與預測,就各疾病來看的藥物評估·SWOT分析,及藥物簡介等資訊。

  • 產品簡介
  • Durvalumab (Imfinzi):頭頸癌
  • Durvalumab (Imfinzi):膀胱癌
  • Durvalumab (Imfinzi):非小細胞肺癌 (NSCLC)
目錄
Product Code: DMKC0142963

Drug Overview

AstraZeneca's Imfinzi is a human monoclonal antibody targeting PD-L1. Programmed death-1 (PD-1) and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and B7 family. The B7 family cell-surface molecules and the CTLA-4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology. The pathways have a similar effect on T-cell immune response but are distinct from each other (Keir et al., 2008).

TABLE OF CONTENTS

  • Product Profiles
  • Imfinzi : Head and neck cancer
  • Imfinzi : Bladder cancer
  • durvalumab : Non-small cell lung cancer (NSCLC)

LIST OF FIGURES

  • Figure 1: Imfinzi for head and neck cancer - SWOT analysis
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Imfinzi for SCCHN
  • Figure 3: Datamonitor Healthcare's drug assessment summary of Imfinzi for SCCHN
  • Figure 4: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 5: Imfinzi for urothelial bladder cancer - SWOT analysis
  • Figure 6: Datamonitor Healthcare's drug assessment summary for Imfinzi in urothelial bladder cancer
  • Figure 7: Datamonitor Healthcare's drug assessment summary for Imfinzi in urothelial bladder cancer
  • Figure 8: Durvalumab for non-small cell lung cancer - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary for durvalumab in non-small cell lung cancer
  • Figure 10: Datamonitor Healthcare's drug assessment summary for durvalumab in non-small cell lung cancer

LIST OF TABLES

  • Table 1: Imfinzi drug profile
  • Table 2: Imfinzi Phase III trials in head and neck cancer
  • Table 3: Imfinzi early-phase data in head and neck cancer
  • Table 4: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 5: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 6: Imfinzi drug profile
  • Table 7: Imfinzi pivotal trial data in urothelial bladder cancer
  • Table 8: Imfinzi ongoing late-phase trials in urothelial bladder cancer
  • Table 9: Durvalumab drug profile
  • Table 10: Durvalumab Phase III trials in non-small cell lung cancer
  • Table 11: Durvalumab early-phase data in non-small cell lung cancer
Back to Top